Trial Profile

A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 18 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs B 013 (Primary) ; Paclitaxel (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Sponsors Shanghai Jiaolian Drug Research and Development

16 Apr 2025 Status changed from recruiting to completed.
27 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
12 May 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com